Sandbox Reserved 992: Difference between revisions
No edit summary |
No edit summary |
||
| Line 36: | Line 36: | ||
With the mechanistic knowledge of β-lactamases, there are two apparent options for clinical treatment of β-lactam resistant bacteria. Scientists could either (a) design an entirely new class of antibiotic that are not reliant on the chemical structure of the β-lactam ring, or (b) use the current arsenal of antibiotics in combination with an inhibitor that will deactivate the β-lactamase. A β-lactamase inhibitor is a compound that could form a tight complex to the active site of the enzyme and causes the β-lactamase to be unable to bind and inactivate another antibiotic molecule. Links to examples Class C β-lactamases, both with and without clinical inhibitors bound, are provided. | With the mechanistic knowledge of β-lactamases, there are two apparent options for clinical treatment of β-lactam resistant bacteria. Scientists could either (a) design an entirely new class of antibiotic that are not reliant on the chemical structure of the β-lactam ring, or (b) use the current arsenal of antibiotics in combination with an inhibitor that will deactivate the β-lactamase. A β-lactamase inhibitor is a compound that could form a tight complex to the active site of the enzyme and causes the β-lactamase to be unable to bind and inactivate another antibiotic molecule. Links to examples Class C β-lactamases, both with and without clinical inhibitors bound, are provided. | ||
{| class="wikitable" style="text-align:center" | |||
|+ Age table | |||
|- | |||
! First name !! Last name !! Age | |||
|- | |||
| Bielat || Adamczak|| 24 | |||
|- | |||
| Blaszczyk || Kostrzewski || 25 | |||
|- | |||
| Olatunkboh || Chijiaku || 22 | |||
|- | |||
| Adrienne || Anthoula || 22 | |||
|- | |||
| Axelia|| Athanasios || 22 | |||
|- | |||
| Jon-Kabat || Zinn || 22 | |||
|} | |||
==References== | ==References== | ||
<references/> | <references/> | ||